NCT06339242

A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis

Name: Clinical Trial NCT06339242
Creator: Jiangsu Province Nanjing Brain Hospital
Keywords: NSCLC, Furmonertinib, Phase 2, drug, clinical trial, China

A Single-arm, Prospective Clinical Study of Double Dose of Furmonertinib Combined With Lateral Ventricular Chemotherapy in the Treatment of EGFR-mutant Lung Cancer With Leptomeningeal Metastasis After Third-generation EGFR-TKIs Resistance

Jiangsu Province Nanjing Brain Hospital·Phase 2·ClinicalTrials.gov·drugRecruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: NSCLC
Drug/Device/Intervention: Furmonertinib
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Jiangsu Province Nanjing Brain Hospital
Location: Nanjing, China

Timeline & enrollment

Phase: Phase 2
Start date: Jan 01, 2024
End date: Jan 31, 2026
Enrollment: 30 participants

Primary outcome

LM-PFS（progression-free survival）,LM-ORR（Objective response rate）

Summary

Leptomeningeal metastasis is a fatal complication of advanced lung cancer. There is no standard treatment for leptomeningeal metastasis after third-generation EGFR-TKIs. The Furmonertinib prototype persists longer in brain tissue, and its metabolites can also penetrate the blood-brain barrier. Ommaya cystlateral ventricle chemotherapy can quickly control the progression of intracranial lesions. The aim of this study is to evaluate the LM progression-free survival (LM-PFS) of Furmonertinib combined with lateral ventricular chemotherapy in the treatment of leptomeningeal metastatic NSCLC after third-generation EGFR-TKIs resistance.

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06339242
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06339242 through Pure Global AI's free database. This Phase 2 trial is sponsored by Jiangsu Province Nanjing Brain Hospital and is currently Recruiting. The study focuses on NSCLC. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.